A Study of Qishenyiqi Dripping Pills in Healthy Participants
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Evaluate the Safety and Tolerability of Continuous Oral Treatment With Qishenyiqi Dripping Pills in Healthy Participants
Sponsor: Tasly Pharmaceutical Group Co., Ltd
Listed as NCT04471298, this PHASE1 trial focuses on Healthy Participants and remains completed. Sponsored by Tasly Pharmaceutical Group Co., Ltd, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tasly Pharmaceutical Group Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .